Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Escudier

Showing results (161-170 of 189) with videos related to

Pageof 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinomaB Melichar, P Koralewski, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settingsJ Beck, G Procopio, E Bajetta, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
ESMO Open|January 18, 2021
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among expertsS Aeppli, M Schmaus, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2010
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC NetworkG G Malouf, P Camparo, S Oudard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyE Calvo, B Escudier, R J Motzer, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]C Dariane, C Pasqualini, N Gaspar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodologyM E Gore, J Bellmunt, T Eisen, et al.
ESMO Open|December 5, 2021
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics studyL Cerbone, D Combarel, A Geraud, et al.
Pageof 19

Showing results (161-170 of 189) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinomaB Melichar, P Koralewski, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settingsJ Beck, G Procopio, E Bajetta, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
ESMO Open|January 18, 2021
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among expertsS Aeppli, M Schmaus, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2010
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC NetworkG G Malouf, P Camparo, S Oudard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 studyE Calvo, B Escudier, R J Motzer, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]C Dariane, C Pasqualini, N Gaspar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodologyM E Gore, J Bellmunt, T Eisen, et al.
ESMO Open|December 5, 2021
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics studyL Cerbone, D Combarel, A Geraud, et al.
Pageof 19